Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Leases (2019 - 2025)

Historic Current Leases for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $2.3 million.

  • Keros Therapeutics' Current Leases rose 2482.5% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 2482.5%. This contributed to the annual value of $2.0 million for FY2024, which is 9681.59% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Current Leases is $2.3 million, which was up 2482.5% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Current Leases registered a high of $2.3 million during Q3 2025, and its lowest value of $436000.0 during Q1 2021.
  • For the 5-year period, Keros Therapeutics' Current Leases averaged around $1.1 million, with its median value being $884000.0 (2022).
  • As far as peak fluctuations go, Keros Therapeutics' Current Leases crashed by 4721.58% in 2022, and later soared by 20392.8% in 2024.
  • Over the past 5 years, Keros Therapeutics' Current Leases (Quarter) stood at $862000.0 in 2021, then plummeted by 47.22% to $455000.0 in 2022, then surged by 120.88% to $1.0 million in 2023, then surged by 96.82% to $2.0 million in 2024, then increased by 17.19% to $2.3 million in 2025.
  • Its Current Leases was $2.3 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.1 million in Q1 2025.